The Administration is considering waiving the intellectual property rights of the COVID-19 vaccine manufacturers, the same drug companies that risked billions to rush and test vaccines to the reach consumers. The argument for waiving these rights is that it will, supposedly, enable more consumers around the globe to get immunized. This commentary shows that waiving intellectual property protections will do little to boost global vaccination rates and may ultimately prevent future vaccine developments for the next global pandemic.